What to Consider When Clinical Trials Are an Option
- Dr. Jay-Jiguang Zhu at UTHealth Houston Neurosciences encourages all glioma patients to discuss clinical trial options early, emphasizing that trials complement standard treatment and may provide access to promising therapies still under investigation.
- Emerging approaches being studied in glioma include dendritic cell vaccines, oncolytic viruses, and CAR T-cell therapy, all of which aim to harness the immune system to target tumors but are not yet FDA-approved for glioblastoma.
- Timing is critical for clinical trial eligibility, as many studies enroll patients before they receive certain treatments, making diagnosis an important time to discuss available trial opportunities with the care team.
“All patients should evaluate clinical trial options,” says Dr. Jay-Jiguang Zhu, a neuro-oncologist and neurologist specializing in brain tumors at UTHealth Houston Neurosciences.
Read More- Dendritic cell vaccines are made from a patient’s own immune cells, trained in a lab to recognize the tumor. Dendritic cells are immune cells that help the body’s defenses identify what to attack.
- Oncolytic viruses are viruses modified in a lab to infect and kill tumor cells while sparing healthy ones.
- CAR T-cell therapy. Doctors collect a patient’s T cells, a type of immune cell, and engineer them to attack the tumor. For glioblastoma, an aggressive type of brain tumor, this is still in early, phase 1 testing, the first stage of research in people, which mainly looks at safety and dosing. In one University of Pennsylvania trial, 18 people with recurrent glioblastoma, meaning their tumor had come back after treatment, received CAR T cells through a small reservoir placed under the scalp. Five of them (28%) were alive more than 18 months later, according to The ASCO Post.
Trials Can Change Care
Trials are how new treatments reach patients.In 2024, the FDA approved vorasidenib (Voranigo) for certain lower-grade gliomas with an IDH mutation. Gliomas are tumors that start in the brain’s supporting cells, and lower-grade gliomas tend to grow more slowly. An IDH mutation is a change in a gene called IDH that is found in some of these tumors. That approval came from a trial of 331 patients in which the drug lowered the risk of the tumor growing or death by 61% compared with a placebo, an inactive look-alike treatment.
However, it’s important to remember that a trial is not a guarantee.
“It does not mean the trial would be better than the standard of care,” Dr. Zhu said. “It’s just an option, and it’s usually a hopeful option.”
RELATED: What to Know Before Enrolling in a Clinical Trial
Why Timing Matters
“Clinical trials depend on the timing and the situation,” Dr. Zhu said. “Sometimes you may not be eligible.”
Many trials enroll only people who are newly diagnosed and have not yet had certain treatments. The vorasidenib trial, for example, did not accept people who had already received chemotherapy or radiation. That’s why it’s worth raising the question with your doctor early.
WATCH: Clinical Trials Can Be Life-Saving for Some
“Your doctor should help you to navigate which one to take,” Dr. Zhu said, whether you are choosing among several trials or between a trial and standard treatment. “That’s why the treatment team is very, very important.”
Questions to Ask Your Care Team
- Are there trials I qualify for now, before I start treatment?
- Does my tumor have molecular features (specific changes in its genes or proteins) that match a specific trial?
- What would I give up, or risk, by joining this trial instead of standard treatment?
- Where is the trial, how often would I need to travel, and who covers the costs?
- If my tumor comes back, which trials might be open to me then?
Learn more about SurvivorNet's rigorous medical review process.
